S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:AXNX

Axonics (AXNX) Stock Price, News & Analysis

$68.90
-0.06 (-0.09%)
(As of 03/27/2024 ET)
Today's Range
$68.75
$69.05
50-Day Range
$67.38
$68.96
52-Week Range
$47.59
$69.68
Volume
1.15 million shs
Average Volume
1.36 million shs
Market Capitalization
$3.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.73

Axonics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
2.7% Upside
$70.73 Price Target
Short Interest
Bearish
5.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.72mentions of Axonics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$6.01 M Sold Last Quarter
Proj. Earnings Growth
106.67%
From $0.30 to $0.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.94 out of 5 stars

Medical Sector

233rd out of 939 stocks

Surgical & Medical Instruments Industry

26th out of 96 stocks

AXNX stock logo

About Axonics Stock (NASDAQ:AXNX)

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Stock Price History

AXNX Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Axonics Responds to ITC Action by Medtronic
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Axonics just downgraded at Morgan Stanley, here's why
Axonics just downgraded at Truist, here's why
Axonics just downgraded at CL King, here's why
Axonics just downgraded at Leerink, here's why
Analyst Scoreboard: 5 Ratings For Axonics
Axonics just downgraded at RBC Capital, here's why
Why Is Axonics (AXNX) Stock Up 20% Today?
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AXNX
Employees
797
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$70.73
High Stock Price Target
$75.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+2.7%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$-6,090,000.00
Pretax Margin
-2.39%

Debt

Sales & Book Value

Annual Sales
$366.38 million
Cash Flow
$0.13 per share
Book Value
$12.59 per share

Miscellaneous

Free Float
50,059,000
Market Cap
$3.51 billion
Optionable
Optionable
Beta
0.57
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives


AXNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares.
View AXNX analyst ratings
or view top-rated stocks.

What is Axonics' stock price target for 2024?

13 Wall Street analysts have issued twelve-month target prices for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they predict the company's stock price to reach $70.73 in the next year. This suggests a possible upside of 2.7% from the stock's current price.
View analysts price targets for AXNX
or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2024?

Axonics' stock was trading at $62.23 at the beginning of 2024. Since then, AXNX stock has increased by 10.7% and is now trading at $68.90.
View the best growth stocks for 2024 here
.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AXNX earnings forecast
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) issued its quarterly earnings results on Wednesday, February, 28th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.07. The firm had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative net margin of 1.66% and a negative trailing twelve-month return on equity of 1.00%. The business's revenue for the quarter was up 27.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.01 EPS.

What guidance has Axonics issued on next quarter's earnings?

Axonics updated its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $109.3 million-$109.7 million, compared to the consensus revenue estimate of $105.5 million.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

Axonics (AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Who are Axonics' major shareholders?

Axonics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.38%), Vanguard Group Inc. (10.32%), Bellevue Group AG (3.62%), Mackenzie Financial Corp (2.47%), Artisan Partners Limited Partnership (2.41%) and Dimensional Fund Advisors LP (1.82%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Kari Leigh Keese, Raymond W Cohen, Raymond W Cohen and Rinda Sama.
View institutional ownership trends
.

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXNX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners